
zzso necrosis factor zzso agents are important therapies for treating Crohn's disease zzso because they may induce and maintain zzso reduce the need for zzso decrease zzso and zzso and heal the zzso Here we provide a practical, evidence-based guide to help clinicians zzso the use of zzso in patients with zzso 

A literature search in the zzso zzso and zzso databases was performed for articles published between 1996 and 2010 describing zzso use in zzso zzso presented at the zzso zzso zzso zzso and zzso zzso references from review articles and published zzso clinical trials, and the zzso prescribing information also were zzso 

When selecting an zzso agent, factors such as zzso safety, zzso patient zzso and the timing and sequencing of therapies should be zzso Important considerations for patient management include dosage selection, use of combination therapy, timing of monitoring treatment response, and evaluation of zzso CD symptoms in a previously responding zzso We recommend that patients initiating zzso receive a loading dose of zzso zzso zzso at Week zzso 2, followed by up to 8 weeks of 40 zzso zzso maintenance therapy prior to determining if there is zzso During therapy, zzso or new symptoms should be fully evaluated to ensure that they are indeed related to underlying inflammation versus other causes zzso zzso infection, zzso acid zzso or irritable zzso Patients experiencing zzso of response or zzso symptoms during maintenance therapy may benefit from dosage zzso to weekly zzso 

zzso for the use of zzso agents in CD, with an emphasis on zzso are reviewed and practical patient management recommendations are zzso 

